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Poster Session II S321time to start L-AMB from HSCT was day 9 (day-34 - day103), and
median duration of usage was 23 (7-151) days. Median time to accel-
erated point (over normal range) and maximum point of serum
creatinine level from the day of starting administration were 6 and
12 (1-29 and 3-73) days respectively. Maximum creatinine level
was significantly higher in patients using for over 23 days compared
with that of shorter. Median replacement dose of potassium and
magnesium were 55 (0-160) mEq/day and 20 (0-35) mEq/day re-
spectively. Median starting dose of L-AMB was 2.5 (2-5) mg/kg.
Breakthrough fungal infections were detected in one patient with
Candida glabrata, one patients with probable aspergillosis and two
probable other fungal infection. All patients were administrated in
combination with several drugs including immune suppressants,
vancomycin. In conclusion, although feasible usage of LAMB, it
should be paid attention to nephrotoxicity especially due to long-
term usage, hypokalemia, kypomagnesemia and breakthrough IFIs
in allogenic HSCT recipients using L-AMB.
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STANDARDIZATION OF CD34 TESTING IS NEEDED FOR PHERESIS PROCE-
DURE DETERMINATION
Fortney, C.A., McKinnon, R., Carey, J., Janakiraman, N. Henry Ford
Hospital, Detroit, MI
Flow Cytometric enumeration of CD34+ and Hematopoietic
StemCells is widely used for determining the adequacy of collection.
Though most centers use ISHAGE approved platforms, there are
wide variations in results affecting the number of collections done.
Variables that could possibly affect these results may include: sample
dexterity influenced by travel time which can increase background
staining of antibody, variations in Flow Cytometry processing
method, Flow Cytometer equipment, gating methods, and skill set
of those completing the testing. CD34 results can affect the determi-
nation by a DC to stop pheresis collections.
We looked at results of 21 products from unrelated donors
received at our Transplant Center (TC) and compared our CD34 re-
sults against the Donor Center’s (DC) CD34 results. Our TC center
CD34 values ranged from 1.90 – 44.60 x 106 CD34/kg of recipient
weight (median 5.33), The DC CD34 values ranged from 3.11 –
20.47 x 106 CD34/kg (median 8.5). In total, 90% of the TC CD34
values were less than the DC results with a range of 21%-417% (me-
dian 61.5%). Product travel time was looked at to determine if it may
have affected the difference in CD34 results. Approximate time be-
tween testing at DC and testing at TC ranged from 6 – 47 hours (me-
dian 34.625). No correlation was found between approximate
elapsed time of sample testing and CD34 results. CD34 values had
no effect on patient engraftment (ANC 500 range 7-25 days, median
15d; Plt 20 range 14-69 days, median 20d).
In summary, there is a wide variation in the estimated number of
CD34+ cells in the product between the DC and TC. The possible
explanations are discussed above. It is not clinically significant in
our group since the number of cells infused is still much higher
than the minimum required for engraftment.
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL RECIPIENTS
DIAGNOSED WITH INVASIVE FUNGAL INFECTION PRIOR TO TRANS-
PLANT PROCEDURE
Gorczynska, E.1, Kalwak, K.1, Owoc-Lempacj, J.1, Janczak, K.1,
Dorobisz, T.1, Kulej, D.1, Ussowicz, M.1, Mielcarek, M.1, Dyla, A.1,
Chybicka, A.1, Musial, J.1, Nawrot, U.2 1Medical University of Wroclaw,
Wroclaw, Poland; 2Medical University of Wroclaw, Wroclaw, Poland
The mortality of allogeneic hematopoietic stem cell (allo-HSC)
recipients transplanted with invasive fungal infection (IFI) is high
due to the risk of infection progression. Eleven (8 children and 3
adults) out of 256 (4.3%) patients who underwent allo-HSCT
from January 2005 to August 2010 at Wroclaw Pediatric Transplant
Center were diagnosed with IFI, classified as possible (4), probable
(2) or proven (5), median 40 days (11 - 60) prior to allo-HSCT. In
spite of persistent IFI, transplant procedures were not postponed
due to advanced underlying diseases: acute leukemias in unstable re-
mission (10) or aplastic anemia (1). Two patients (1 Rhisopus dissem-
inated infection, 1 probable lung Aspergillosis) died of lung
insufficiency (septic shock or capillary leak syndrome) before en-
graftment. Both received combined antifungal treatment: amphoter-icin lipid complex (ABLC) or liposomal formulation (L-AMB) +
posaconazole (PCZ) or echinocandine. One patient with proven As-
pergillosis treated with ABLC followed by Posa died of a leukemia
relapse 1 year post allo-HSCT without symptoms of IFI. Eight pa-
tients with previous lung infection are alive for median 17,6 months
(2 - 69. 5) post allo-HSCT. Complete resolution of lung infiltrates
was achieved in 6 and partial in one (still on treatment). In 5 of
them several antifungal drugs (VCZ, PCZ, LAMB, echinocandins)
were used in different sequences as monotherapy (switched one to
other according to treatment response or toxicity). Two patients re-
ceived combined therapy with echinocandine + VCZ or ABLC. In-
tensive antifungal treatment was followed by secondary
prophylaxis with itraconazole (3), PCZ (2) or VCZ (2) for median
6 months (2-22). Three out of 7 patients underwent resection of per-
sistent pulmonary lesions. One patient with possible lung Aspergil-
losis was treated with L-AMB switched to VCZ followed by PCZ
until 13 months post HSCT which resulted in resolution of lung le-
sions reappearing one month later Then antifungal therapy was
given again (VCZ followed by PCZ) for 10 months. Five years after
allo-HSCT and 2.5 years off antifungal treatment, he is well, how-
ever CT imaging revealed new lung infiltrates.
Conclusions: Active IFI is not a contraindication for allo-HSCT.
IFI treatment has to be intensive and include secondary prophylaxis
with anti-mold effective drugs. In case of insufficient response to an-
tifungal monotherapy both combination treatment and surgical
intervention may be used as salvage option.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE
MYELOID LEUKEMIA – THE RETROSPECTIVE ANALYSIS
Vondrakova, J.1, Belohlavkova, P.2, Zapletalova, J.3, Raida, L.1, Zak, P.2,
Jebavy, L.2, Voglova, J.2, Zavrelova, A.2, Pikalova, Z.1, Skoumalova, I.1,
Jarosova, M.1, Faber, E.1, Maly, J.2, Indrak, K.1 1University Hospital,
Olomouc, Czech Republic; 2University Hospital, Hradec Kralove, Czech
Republic; 3Medical Faculty, Palacky University, Olomouc, Czech Republic
Background: Myelodysplastic syndromes (MDS) are the heteroge-
nous group of diseases with a different risk of development to acute
leukemia (AL). The allogeneic stem cell transplantation (alloSCT) is
one of the treatment possibilities that is more accessible thanks to
availability of recent conditioning regimes. Many questions are still
open. The goal of the retrospective analysis was the evaluation of al-
loSCTs performed in two transplantation centres to estimate the im-
portance of alloSCT for MDS patients (pts), to evaluate prognostic
parametres and the course of alloSCTs and overall survival (OS). Pa-
tients characteristics: The cohort consisted of 30 pts, male:female ra-
tio was 1:1, transplanted in 1997 – 2010, the age were 23 – 63 year
(median 56). According the WHO 2001 classification the pts were
initially classified as: 2 (7%) 5q- sy, 2 (7%) RARS, 9 (30%)
RCMD, 6 (20%) RAEB I, 11 (36%) RAEB II, according to IPSS
as: 2 (6%) low risk, 11 (37%) intermediate-1, 11 (37%) intermedi-
ate-2, 6 (20%) high risk. In 13 cases (43%) alloSCT was performed
in leukemic phase, in majority of cases after induction/consolidation
chemotherapy. 6 (20%) pts underwent alloSCT during the progres-
sion into more advanced MDS and 11 (37%) in phase of stabile dis-
ease. 11 pts (37%) underwent myeloablative conditioning regime
and 19 (63%) pts reduced intensity regime. 14 transplantations
were from sibling donors, 16x from unrelated donors, only in 1
case was used bone marrow.
Results: Median of follow-up from MDS diagnosis was 33 months,
from alloSCT 15 months. Transplantation was performed in median
of 11 months from diagnosis of MDS. 11 pts died in the whole cohort
– the reasonwas the progressionof disease (4x), infection complications
(4x), GVHDand current infection (3x). It dealt initially about themost
riskyMDS,8 (27%) transformed intoAL, accordingIPSS4 (13%)were
initially high risk, 7 (23%) intermediate (int-1 and int-2).Median from
diagnosis was 12 and from alloSCT 3months. Other pts have received
long time remission and in the low risk MDS transfusion dependence
was removed and the quality of life was outstandingly improved. At
the moment 19 (63%) pts live with median of follow-up 49 month
fromMDS diagnosis and 27 months from alloSCT.
Conclusion: It is possible curatively influence MDS or secondary
AL in favour of patient exploiting aloSCT. Consideration of this cu-
rative possibility should have become routine part of diagnostic-
prognostic algorithm in MDS patients.
